A Pilot Study of Ipilimumab in Subjects With Stage IV Melanoma Receiving Palliative Radiation Therapy
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 20 Jan 2017 Planned End Date changed from 1 Jun 2016 to 1 Dec 2018.
- 20 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 06 Nov 2015 Planned End Date changed from 1 Jun 2015 to 1 Jun 2016, as reported by ClinicalTrials.gov.